Investing.com -- Bank of America has reinstated coverage of Bausch + Lomb Corp (NYSE:BLCO) with an "underperform" rating and a price target of $18, amid reduced prospects of a private equity buyout.

The rating of the stock follows a report that Blackstone (NYSE:BX) pulled out of a consortium considering a takeover of the eye care company. Bausch&Lomb’s shares, which had risen 33% since mid-September on buyout speculation, fell 12% after the news.

“A takeout is not imminent and we would expect it to rekindle investor concerns on the timing/likelihood of the spin. BLCO’s fundamentals have been solid over the last several quarters but we think the stock will be a relative underperformer without more clarity on the spin,” analyst wrote.

The uncertainty around a potential spin-off from its parent company, Bausch Health, remains a significant overhang. The parent company still owns 88% of Bausch&Lomb and has provided limited details on separation plans since the company’s IPO in May 2022.

BofA noted that while Bausch&Lomb has shown solid growth in sales and margins, investor focus is likely to remain on the spin-off’s timing and feasibility. Without clarity on separation, the stock is expected to underperform relative to the market.

Related Articles

Greece to buy artillery systems from Israel and drones from US, officials say

Column-Bleak times for copper smelters as conversion fees slump: Andy Home